[Clinical study of combination chemotherapy with continuously infused peplomycin (PEP), cis-dichlorodiammineplatinum (II) (CDDP) and mitomycin C (MMC) (PPM therapy)].
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D017663:Peplomycin
D008937:Mitomycins; D001761:Bleomycin; D016685:Mitomycin; D017663:Peplomycin; D002945:Cisplatin